Thus, our findings both support existing guideline recommendations on the use of SGLT2 inhibitors in patients with T2DM across a spectrum of ASCVD, and suggest an opportunity for further evaluation of the efficacy and safety of SGLT2 inhibitors among patients with acute ASCVD events. The gene discussed is SLC5A2; the disease is atherosclerosis.